Heparin-Natrium Braun

Heparin-Natrium Braun is an injectable solution containing the anticoagulant heparin sodium. Marketed in the European Union, this prescription‑only product is supplied as a sterile liquid for intravenous or subcutaneous administration. It is used to inhibit clot formation by potentiating antithrombin III, thereby reducing thrombin and factor Xa activity. The formulation does not specify a fixed strength in the label. It is typically stored under controlled temperature conditions and requires aseptic handling before use.

Heparin-Natrium Braun is indicated for several thrombo‑embolic conditions where anticoagulation is required.

- Prevention of deep‑vein thrombosis (DVT) in patients undergoing major surgery or who are immobilized for prolonged periods. - Treatment and prophylaxis of pulmonary embolism, reducing the risk of life‑threatening blockage of pulmonary arteries. - Management of acute coronary syndrome, including unstable angina and myocardial infarction, to limit clot propagation in coronary vessels. - Prevention of clot formation during cardiac or vascular interventional procedures such as angioplasty, stent placement, or bypass grafting. - Use in patients with atrial fibrillation who have an elevated risk of stroke, although this may be considered off‑label in certain jurisdictions. - Adjunct anticoagulation during extracorporeal circulation procedures such as cardiopulmonary bypass or hemodialysis to maintain circuit patency.

Adverse reactions to Heparin‑Natrium Braun vary in frequency and severity; they are reported in clinical practice and post‑marketing surveillance.

Common: - Minor bleeding at the injection site. - Bruising or hematoma formation around the administration area. - Nausea or mild gastrointestinal discomfort. - Transient elevation of liver enzymes detected on routine labs. - Injection site pain, erythema, or localized swelling.

Serious: - Major hemorrhage, including internal bleeding or severe external bleeding. - Heparin‑induced thrombocytopenia (HIT) with a rapid drop in platelet count. - Allergic reactions ranging from urticaria to anaphylaxis. - Spontaneous spinal or epidural hematoma causing neurologic deficits. - Acute adrenal hemorrhage leading to adrenal insufficiency.

Before initiating Heparin‑Natrium Braun, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Assess individual bleeding risk, including recent surgery, trauma, or active gastrointestinal bleeding. - Review baseline platelet count and coagulation parameters such as aPTT and PT/INR before starting therapy. - Use reduced initial doses in patients with significant renal or hepatic impairment. - Avoid use in individuals with known hypersensitivity to heparin or pork‑derived products. - Monitor platelet counts regularly for signs of heparin‑induced thrombocytopenia during treatment. - Adjust dosing or discontinue therapy if uncontrolled bleeding or severe thrombocytopenia occurs.

Heparin‑Natrium Braun may interact with other agents that affect hemostasis or drug metabolism; awareness of these interactions helps prevent adverse events.

Avoid: - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without appropriate dose adjustment. - Combination with antiplatelet agents such as aspirin, clopidogrel, or ticagrelor. - Concomitant administration of fibrinolytic drugs (e.g., alteplase, streptokinase) that increase bleeding risk. - Use together with non‑steroidal anti‑inflammatory drugs (NSAIDs) that can potentiate hemorrhage.

Use with caution: - Dual therapy with low‑molecular‑weight heparins or fondaparinux, requiring close laboratory monitoring. - Concurrent use of selective serotonin reuptake inhibitors (SSRIs) or other medications that impair platelet function. - Overlap with high‑dose vitamin K antagonists (e.g., warfarin) where INR monitoring is essential.